Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 11/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.39 |
| ▸ | RXRB | P28702 | 2/20 | 0.39 |
| ▸ | RXRG | P48443 | 2/20 | 0.39 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 7/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 6/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL3427753 | 0.85 | CACNA1H (0.41) | EGLN1CACNA1HCACNA1BCACNA1CCACNA1G | |
| SCHEMBL12495908 | 0.81 | CACNA1H (0.42) | EGLN1CACNA1HCACNA1BCACNA1CCACNA1G | |
| SCHEMBL3424888 | 0.81 | HSD17B10 (0.49) | CACNA1HCACNA1BCACNA1CCACNA1G | |
| SCHEMBL15844285 | 0.81 | CACNA1H (0.53) | EGLN1CACNA1HCACNA1BCACNA1CCACNA1G | |
| SCHEMBL15844077 | 0.79 | CACNA1H (0.56) | CACNA1HCACNA1G | |
| SCHEMBL15843980 | 0.79 | CACNA1H (0.56) | CACNA1HCACNA1BCACNA1CCACNA1G | |
| SCHEMBL15850879 | 0.79 | CACNA1H (0.43) | CACNA1HCACNA1BCACNA1CCACNA1G | |
| SCHEMBL15844374 | 0.78 | CACNA1H (0.70) | CACNA1HCACNA1BCACNA1CCACNA1G | |
| SCHEMBL15844774 | 0.78 | CACNA1B (0.52) | EGLN1CACNA1HCACNA1BCACNA1CCACNA1G | |
| SCHEMBL15844641 | 0.78 | CACNA1H (0.53) | CACNA1HCACNA1BCACNA1CCACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620391-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2014-01-15 | — | — | EP | disclosed |
| US-7696205-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080108678-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-7291615-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-20040235836-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235836-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | EGLN1 3013/4885CACNA1H 1151/4885RXRA 707/4885 |
| US-20080108678-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, CCR1 | EGLN1 3201/4885CACNA1H 1289/4885RXRA 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.